ArriVent BioPharma opened higher at $13.55, compared with its previous close of $13.51. In the last trading session, the stock traded between $12.89 and $13.62. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 3 years ago in ArriVent BioPharma is now worth
$ 65.36
Resulting in a loss of
$ 34.64 (34.64%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 12 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.43 (-3.21%)
Day High
$13.62
Day Low
$12.89
Day Open
$13.55
Prev Close
$13.51
Volume
6,39,299
1W Return
-3.10%
1M Return
-20.53%
3M Return
-58.34%
6M Return
-54.96%
1Y Return
-32.55%
Fundamentals
Market Cap ($ Mn)
676
PE Ratio
-
PB Ratio
3.98
PEG Ratio
-
ROE
-62.89%
ROCE
-67.13%
EPS (TTM)
$-0.88
Investment Returns
1 Week
-3.10%
1 Month
-20.53%
3 Months
-58.34%
6 Months
-54.96%
9 Months
-39.54%
Financials
Quarterly
All values in $ Mn
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
0.0
Sep 26
Updates
10Nov
ArriVent BioPharma Q3 Results: Loss narrows to $(0.81), beats estimate
ArriVent BioPharma reported a Q3 loss of $(0.81) per share. The figure beat the analyst consensus estimate of $(1.05). Losses narrowed by 2.41% compared to the same period last year. Quarterly sales were reported at $5.0 million.
3 days ago
20Oct
B. Riley maintains Buy on ArriVent BioPharma, cuts price target to $29
B. Riley Securities maintains a Buy rating on ArriVent BioPharma. Price target lowered from $45 to $29 by analyst Kalpit Patel. The revised target reflects a $16 reduction in valuation.
23 days ago
19Oct
ArriVent publishes firmonertinib data showing 68% response rate
Firmonertinib shows 68% confirmed ORR at 240 mg dose in Phase 1b trial. Median progression-free survival reaches 16.0 months at higher dose level. Intracranial ORR of 47% observed in patients with baseline brain metastases. ctDNA clearance correlates with improved response rates and survival times.
24 days ago
16Oct
BTIG reiterates Buy on ArriVent BioPharma, maintains $29 target
BTIG analyst Jeet Mukherjee reiterated a Buy rating on ArriVent BioPharma. The $29 price target was maintained by the research firm.
27 days ago
14Oct
Three law firms investigate ArriVent over FURVENT trial failure
Three law firms now investigate ArriVent BioPharma over FURVENT trial failure. Stock closed at $15.01 on October 6, 2026, down 47.3% from previous day. Kirby McInerney cites misleading preclinical data and delayed result timelines. Levi & Korsinsky flags $250 million equity offering filed before trial readout.
1mo ago
13Oct
ArriVent BioPharma doses first patient in Phase 1 trial of ARR-002
ArriVent BioPharma dosed the first patient in the US Phase 1 trial of ARR-002. ARR-002 is a dual-target ADC for ovarian and endometrial cancer. The trial marks the second ADC from ArriVent's portfolio to enter the clinic. ArriVent licensed Greater China rights to Shanghai Allist Pharmaceuticals in August 2026.
